Erratum to “Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists” [Bioorg. Med. Chem. Lett. 16 (2006) 4652–4656]

Bioorganic & Medicinal Chemistry Letters 16 (2006) 5472

Erratum

Erratum to ‘‘Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists’’ [Bioorg. Med. Chem. Lett. 16 (2006) 4652–4656] Dann L. Parker, Jr.,a,* Dongfang Meng,a Ronald W. Ratcliffe,a Robert R. Wilkening,a Donald M. Sperbeck,a Mark L. Greenlee,a Lawrence F. Colwell,a Sherrie Lambert,a Elizabeth T. Birzin,b Katalin Frisch,b Susan P. Rohrer,b Stefan Nilsson,c Ann-Gerd Thorsellc and Milton L. Hammonda b

a Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA Department of Atherosclerosis and Endocrinology, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA c KaroBio AB, Novum, S-14157 Huddinge, Sweden

The publisher regrets that the structures in Figure 1 are labeled incorrectly. The corrected figure appears here. R2

O

R2

4

O

O

R2

2 9a 7

HO

R1 8

I

HN N

R1 II

HN N N

R1 III

1 R1 = Bu R 2 = Br

Figure 1. ERb ligands based on tetrahydrofluorenones.

DOI of original article: 10.1016/j.bmcl.2006.05.103. * Corresponding author. Tel.: +1 732 594 4586; fax: +1 732 594 9556; e-mail: [email protected] 0960-894X/$ - see front matter Ó 2006 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2006.05.106